CD157 important in malignant pleural mesothelioma -
By Laura Cowen, medwireNews Reporter
CD157 plays a key role in the progression of malignant pleural mesothelioma (MPM) and may be useful in stratifying patients into different prognostic groups, the Italian research suggests.
CD157 is known to contribute to tumor progression in ovarian cancer by promoting mesenchymal parallel differentiation between ovarian cancer and mesothelial indicate that CD157 may also be involved in MPM, explained Ada Funaro ( Turin University) and colleagues.
To test this hypothesis, Funaro and team conducted in vitro and in vivo using human cell lines MPM and MPM samples of surgical tissue.
using the reaction in reverse transcriptase polymerase chain and flow cytometry, they detected CD157 mRNA and protein expression in two of five epithelioid cell lines and MPM in one of the three cell lines biphasic MPM.
Expression was also detected by immunohistochemistry in 85.2% of 81 MPM samples of surgical tissues and was evenly distributed between epithelioid (86.5%) and biphasic (84.0%) tumors.
The statistical analysis revealed that CD157 expression was not correlated with sex, patient age at surgery, histology, history of asbestos, stage of the disease or the prognosis of patients when the MPM 81 surgical samples were stratified by the median CD157 histology (H) -Score 50.
Similarly, when the data were analyzed according histotype, it there was no correlation between survival and CD157 H-score in patients of epithelioid tumors.
However, the reverse was true for biphasic MPM, where a high CD157 H-score (> 50) was significantly associated with worse survival compared to a low score, a median of 13.1 against 20.4 months, and a hazard ratio of 2.43.
This finding has prompted researchers to further investigate the influence of CD157 on the behavior of tumor cells in vitro.
They report that, in cell lines biphasic MPM, knockdown of CD157 in CD157 positive cells significantly reduced cell growth, motility and invasiveness, whereas forced expression of CD157 in cell negative CD157 strengthened each of these variables. In contrast, no effect was observed in the lines of epithelioid cells.
In addition, increased expression of CD157 in cell lines BPM biphasic correlated with increased resistance to platinum-based chemotherapy, by the activation of the mTOR pathway, which is a known contributor to mesothelioma progression.
and patients with biphasic MPM and an expression of high CD157 receiving postoperative platinum based chemotherapy showed a trend towards reduced survival compared to those with low expression of CD157 which received the same type of treatment.
"These data suggest that CD157 may be a promising candidate as a predictive marker of response to platinum-based therapy in MPM biphasic patients," Funaro and co-authors conclude in Oncotarget .
medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon